Natriumoksybat Kalceks (Sodium Oxybate)

Sodium oxybate, the active ingredient in Natriumoksybat Kalceks, is a gamma‑hydroxybutyrate (GHB) analog presented as an oral formulation for oral use. It is indicated for the treatment of narcolepsy with cataplexy in adult patients. GNH USA supplies Natriumoksybat Kalceks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sodium oxybate acts on the central nervous system to manage symptoms of a specific sleep disorder. - Narcolepsy with cataplexy: Reduces the frequency of cataplexy episodes and improves nighttime sleep quality.

Sodium oxybate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: sensation of light‑headedness. - Vomiting: occasional emesis. - Insomnia: difficulty initiating sleep. - Weight loss: reduced appetite.

Serious or Rare Side Effects: - Respiratory depression: reduced breathing effort. - Seizures: rare convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Confusion or delirium: altered mental status. - Abuse potential: risk of dependence with misuse. - Anaphylaxis: rare severe allergic reaction.

When prescribing sodium oxybate, several safety considerations are essential. - Dose titration: Initiate at the lowest effective dose and increase only under medical supervision. - Alcohol avoidance: Concurrent intake can cause profound CNS depression. - Respiratory monitoring: Observe patients with sleep‑disordered breathing. - Pregnancy: Use only if benefits outweigh potential risks; data are limited. - Renal impairment: Adjust dosing in patients with reduced kidney function. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture.

Sodium oxybate can interact with other central nervous system depressants and certain serotonergic agents.

Major Interactions (Avoid): - Alcohol: additive CNS depression may be life‑threatening. - Opioids: combined use increases risk of respiratory depression. - Benzodiazepines: may cause excessive sedation and respiratory compromise.

Moderate Interactions (Monitor Closely):\n- Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome; monitor symptoms. - Antihistamines: may enhance sedative effects; observe patient response.